Gastric cancer and tumor growth regulation. Study of cell proliferation markers and protein complex P53/p2lWAF1/CIP1/mdm-2;Cáncer gástrico y regulación del crecimiento tumoral. Estudio de marcadores de proliferación celular y del complejo proteínas p53/p21WAF1/CIP1/mdm-2

Revista Medica de Chile

Volumn 128, Issue 2, 2000, Pages 127-136

  Villaseca H, Miguel ^a,b   Araya O, Juan Carlos ^a   Roa E, Iván ^a   Roa S, Juan Carlos ^a  

^a UNIVERSIDAD DE LA FRONTERA   (Chile)

^b NONE   (Chile)

Author keywords

Gastrectomy; Immunohistochemistry; Neoplasm proteins; Stomach neoplasms

Indexed keywords

CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; KI 67 ANTIGEN; MDM2 PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; PROTEIN MDM2; PROTEIN P53; TUMOR MARKER;

ARTICLE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MIDDLE AGED; MITOSIS; PATHOLOGY; STOMACH TUMOR; SURVIVAL;

CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; MITOSIS; NUCLEAR PROTEINS; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034136687     PISSN: 00349887     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. MOSKALUK CA, HEITMILLER R, ZAHURAK M, SCHWAB D, SIDRANSKY D, HAMILTON SR. p53 and p21(WAF1/CIP1/SDI1) gene products in Barrett esophagus and adenocarcinoma of the esophagus and esophagogastric junction. Hum Pathol 1996; 27: 1211-20.
2. OGAWA M, MAEDA K, ONODA N, CHUNG YS, SOWA M. Loss of p21WAF1/CIP1 expression correlates with disease progression in gastric carcinoma. Br J Cancer 1997; 75: 1617-20.
3. MATEO M, SÁEZ A, SÁNCHEZ-BEATO M, GARCÍA P, SÁNCHEZ-VERDE I, MARTÍNEZ J ET AL. Expression of P21WAF1/CIP1 in fetal and adult tissues: simultaneous analysis with Ki67 and p53. J Clin Pathol 1997; 50: 645-53.
4. FINLAY C. The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol Cell Biol 1993; 13: 301-6.
5. AN WG, CHUMAN Y, FOJO T, BLAGOSKLONNY MV. Inhibitors of transcription, proteasome inhibitors, and DNA-damaging drugs differentially affect feedback of p53 degradation. Exp Cell Res 1998; 244: 54-60.
6. SOSLOW RA, ALTORKI NK, YANG G, XIE D, YANG CS. mdm-2 expression correlates with wild-type p53 status in esophageal adenocarcinoma [In Process Citation]. Mod Pathol 1999; 12: 580-6.
7. BUTZ K, GEISEN C, ULLMANN A, ZENTGRAF H, HOPPESEYLER F. Uncoupling of p21WAF1/CIP1/SDI1 mRNA and protein expression upon genotoxic stress. Oncogene 1998; 17: 781-7.
8. TAHAN S, NEUBERG D, DIEFFENBACH A, YACOUB L. Prediction of early relapse and shortened survival in patients with breast cancer by proliferating cell nuclear antigen. Cancer 1993; 71: 3552-9.
9. ROA I, ARAYA J, SHIRAISHI T, YATANI R, VILLASECA M, WISTUBA I ET AL. Proliferating cell nuclear antigen in gallbladder carcinoma. Histopathol 1993; 23: 179-83.
10. ROSA J, MENDES R, FILIPE M, MORRIS R. Measurement of cell proliferation in gastric carcinoma: comparative analysis of Ki-67 and proliferative cell nuclear antigen. Histochem J 1992; 24: 93-101.
11. JAIN S, FILIPE MI, HALL PA, WASEEM N, LANE DP, LEVISON PA. Prognostic value of proliferating cell nuclear antigen in gastric carcinoma. J Clin Pathol 1991; 44: 655-9.
12. PRELICH G, TAN C, KOSTURA M, MATHEWS M, SO G, DOWNEY K ET AL. Functional identity of proliferating cell nuclear antigen and a DNA polymerase-δ auxiliary protein. Nature 1987; 326: 517-20.
13. BROWN DC, GATTER KC. Monoclonal antibody Ki-67: its use in histopathology. Histopathol 1990; 17: 489-503.
14. GERDES J, SCHWAB U, LEMKE H, STEIN H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983; 31: 13-20.
15. VERHEIJEN R, KUIJPERS HJH, DRIEL R, BECK JLM, DIERENDONCK JH, BRAKENHOFF GJ ET AL. Ki-67 detects a nuclear matrix-associated proliferation-related antigen. II. Localization in mitotic cells and association with chromosomes. J Cell Sci 1989; 92: 531-40.
16. DIERENDONCK JH, KEIJZER R, VELDE CJH, CORNELISSE CJ. Nuclear distribution of the Ki-67 antigen during the cell cycle: comparison with growth fraction in human breast cancer cell. Cancer Res 1989; 49: 2999-3006.
17. CATTORETTI G, BECKER MHG, KEY G, DUCHROW M, SCHLÜTER C, GALLE J ET AL. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB-1 and MIB3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 1992; 168: 357-63.
18. LAURÉN P. The two histological main types of gastric carcinoma: diffuse and so-called Intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Path Microbiol Scand 1965; 64: 31-49.
19. SCHAFER KA. The cell cycle: a review. Vet Pathol 1998; 35: 461-78.
20. ROSA J, MENDES R, FILIPE M, MORRIS W. Measurement of cell proliferation in gastric carcinoma: comparative analysis of Ki-67 and proliferative cell nuclear antigen. Hictochem J 1992; 24: 93-101.
21. FILIPPONI F, ROMAGNOLI P. Evaluation of the mitotic index of human colonic mucosa: Results of two different observers. Path Res Pract 1987; 182: 67-71.
22. AKAMA Y, YASUI W, KUNIYASU H, YOKOZAKI H, TAHARA H, NODA A ET AL. [Expression of sdi1, a potent inhibitor of cdk2 kinase, cdk2 and G1 cyclins and mutation of sdi1 in human gastric carcinomas]. Gan To Kagaku Ryobo 1995; 22 Suppl 2: 180.
23. WU TT, KORNACKI S, RASHID A, YARDLEY JH, HAMILTON SR. Dysplasia and dysregulation of proliferation in foveolar and surface epithelia of fundic gland polyps from patients with familial adenomatous polyposis. Am J Surg Pathol 1998; 22: 293-8.
24. CHO JH, KIM WH. Altered topographic expression of p21WAF1/CIP1/SDI1, bc12 and p53 during gastric carcinogenesis. Pathol Res Pract 1998; 194: 309-17.
25. GOMYO Y, IKEDA M, OSAKI M, TATEBE S, TSUJITANI S, IKEGUCHI M, ET AL. Expression of p21 (waf1/cip1/sdi1), but not p53 protein, is a factor in the survival of patients with advanced gastric carcinoma. Cancer 1997; 79: 2067-72.
26. STRICKLER JG, ZHENG J, SHU Q, BURGART LJ, ALBERTS SR, SHIBATA D. p53 mutations and micro-satellite instability in sporadic gastric cancer: when guardians fail. Cancer Res 1994; 54: 4750-5.
27. MAYO LD, TURCHI JJ, BERBERICH SJ. Mdm-2 phosphorylation by DNA dependent protein kinase prevents interaction with p53. Cancer Res 1997; 57: 5013-6.
28. STEFANOU DG, NONNI AV, AGNANTIS NJ, ATHANASSIADOU SE, BRIASSOULIS E, PAVLIDIS N. p53/MDM-2 immunohistochemical expression correlated with proliferative activity in different subtypes of human sarcomas: a ten-years follow-up study. Anticancer Res 1998; 18: 4673-81.
29. ZIRBES TK, LORENZEN J, BALDUS SE, MOENIG SP, WOLTERS U, OTTLIK A ET AL. Apoptosis and expression of bcl-2 protein are inverse factors influencing tumour cell turnover in primary carcinoid tumours of the lung. Histopathology 1998; 33: 123-8.